{"schema_version":"secwatch.filing_event.v1","accession":"0001829126-25-003009","form_type":"8-K","ticker":"BKHA","cik":"0002000775","company_name":"Black Hawk Acquisition Corp","filed_at":"2025-04-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.665911+00:00","generated_at":"2026-05-23T04:16:35.664080+00:00","sec_items":["1.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Black Hawk SPAC enters $70M merger with Vesicor Therapeutics; p53 cancer therapy focus","bullets":["Total equity value $70M; Aggregate Merger Consideration = $70M divided by Redemption Price.","Vesicor must secure at least $10M in PIPE financing as condition to close.","Post-merger CEO: Luo Feng, CFO: Michael Bowen, COO: Warren Hosseinion Jr.; 5-member board.","Lock-up: 6 months for PubCo shares, 12 months for Vesicor warrant holders.","Break-up fee of $1M payable by breaching party; termination rights for failure to secure PIPE or deliver audited financials by June 10, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-25-003009","json":"https://secwatch.observer/filing/0001829126-25-003009.json","markdown":"https://secwatch.observer/filing/0001829126-25-003009.md","text":"https://secwatch.observer/filing/0001829126-25-003009.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2000775/000182912625003009/0001829126-25-003009-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2000775/000182912625003009/blackhawk_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T04:16:35.664080+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}